A
Alzprotect
Biotech & Life Sciences · Loos, France · Founded 2007
Biopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases MoreLess
Alzprotect is a biopharmaceutical company focused on the development of drug candidates aimed at treating neurodegenerative diseases such as Alzheimer's disease (AD) and tauopathies, including Progressive Supranuclear Palsy (PSP). The company operates in the healthcare and pharmaceutical market, targeting patients suffering from these debilitating conditions. Alzprotect's business model revolves around the discovery, development, and clinical trials of its drug candidates. Revenue is generated through the successful progression of these drugs through clinical trials, leading to potential partnerships, licensing agreements, and eventual commercialization. The company serves a critical need in the medical community by addressing diseases with significant unmet medical needs.
Keywords: biopharmaceutical, drug development, neurodegenerative diseases, Alzheimer's, tauopathies, clinical trials, healthcare, pharmaceutical, Progressive Supranuclear Palsy, medical research.
Company overview
Alzprotect company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2007
- Headquarters
- Loos, France
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 61.4
Valuation & funding
Alzprotect funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jun 2022 | $340K | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| SERIES B✓Equity / VC | Jan 2018 | $15M | $62M | Finovam · Xerys · Nord France Amorcage | — |
| SERIES A✓Equity / VC | Jun 2014 | $2.2M | $8.8M | Nord France Amorcage | — |
| SEED✓Equity / VC | Nov 2008 | $0 | — | Finorpa | — |
| SPINOUT✓Other financing | Nov 2007 | $0 | — | INSERM · University of Lille | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin | Profit | Margin |
|---|---|---|---|---|
| 2026 | −$3.1M | — | −$2.3M | — |
| 2025 | −$3.1M | — | −$2.3M | — |
| 2024 | −$3.1M | — | −$2.3M | — |
| 2023 | −$3.1M | — | ||
| 2022 | −$3.1M | — | ||
| 2021 | −$3.1M | — | ||
| 2020 | −$3.1M | — |
Growth signals
Alzprotect website traffic
Latest recorded traffic for Alzprotect is 1.2K monthly website visits, up 48.1% over the last three months. Alzprotect's team declined 25% over the past year.
Comparisons
Alzprotect compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Alzprotect's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Alzprotect's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Alzprotect has talent and traffic
team presence
In the news
Latest news about Alzprotect
Recent press, funding announcements, and product moves mentioning Alzprotect — open to read from the original sources.
Market sentiment
What the market is saying about Alzprotect
An AI-synthesized read of the highest-engagement posts about Alzprotect on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alzprotect’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.